Table 2.
Patient demographics, disease parameters and treatment
| Patient characteristic (N = 25) | Number or median (range) |
|---|---|
| Age, years | 55 (36–72) |
| Sex, male/female: | 15/10 |
| Chain isotype | |
| IgG | 16 |
| IgA | 5 |
| Light chain | 4 |
| ISS stage | |
| I | 10 |
| II | 11 |
| III | 4 |
| DS‐PLUS stage | |
| I | 1 |
| II | 3 |
| III | 21 |
| Induction regimen | |
| PAD | 17 |
| CVD | 3 |
| VTD | 4 |
| MPV | 1 |
| Bone marrow percentage plasma cells | 65 (13–90) |
| Beta‐2 microglobulin (mg/l) | 3·5 (1·3–11·3) |
| Albumin (g/l) | 40 (30–53) |
| Creatinine | 79 (56–105) |
| Genetic risk group | |
| Standard risk | 16 |
| High risk | 9 |
ISS, international staging system; DS‐PLUS, durie‐salmon PLUS staging; PAD, bortezomib, doxorubicin, dexamethasone; CVD, cyclophosphamide, bortezomib, dexamethasone; VTD, bortezomib, thalidomide, dexamethasone; MPV, melphalan, prednisone, bortezomib.